

For people 9 years and older with primary hyperoxaluria type 1 (PH1)
and relatively preserved kidney function

Explore the path of possibilities with Rivfloza[®]

Look forward to the journey ahead with a once-monthly treatment
that lowers and keeps urinary oxalate levels under control.



Actor portrayals.

What is Rivfloza[®]?

Rivfloza[®] is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.

It is not known if Rivfloza[®] is safe and effective in children younger than 9 years of age.

Important Safety Information

What are the possible side effects of Rivfloza[®]?

The most common side effects of Rivfloza[®] include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.

Please click [here](#) for Prescribing Information.


 rivfloza[®]
(nedosiran) injection
80mg, 128mg, 160mg

What is primary hyperoxaluria (PH)?

PH is a rare disease in which the liver does not make enough of a certain protein to prevent oxalate (a natural waste product) from building up in the body.




Primary Hyperoxaluria



- PH is an inherited (genetic) disease, meaning it is caused by a change in a gene that is passed down from both parents to a child
- PH affects both children and adults
- There are 3 types of PH: PH1, PH2, and PH3
 - **PH1 is the most commonly clinically diagnosed type of PH**


PH1 may affect people differently or change over time



Kidney stones are the most common symptom of PH1 but are not the only symptom of the disease.




PH1 can cause **kidney damage** that may progress to end-stage kidney disease, requiring dialysis and possible **liver-kidney transplant**.



Over time, PH1 can lead to **systemic oxalosis**, a condition that affects organs throughout the body, including the eyes, heart, skin, and bones.

In PH1, overproduction of oxalate can lead to progressive kidney damage

When too much oxalate is made in the liver, the kidneys are not able to eliminate (remove) enough of it in urine. This causes oxalate to attach to calcium, forming crystals inside the kidneys. These crystals can group together to form kidney stones.



- **Even in the absence of symptoms**, oxalate can continue to build up and cause damage throughout the body in people with PH1
- It is important to **intervene as early as possible** in the disease process and get oxalate levels under control

Treatment challenges




Most standard treatments for PH1 do not address the underlying cause of the disease.

- **Only a subset of people** with PH1 respond to vitamin B6 supplementation
- Hydration (increased daily intake of water) can be **challenging to maintain**

For people 9 years and older with PH1 and relatively preserved kidney function

Rivfloza® helps prevent overproduction of oxalate in the liver



Clinical study design

Rivfloza® was studied for 6 months in 35 people with PH1 or PH2 and relatively preserved kidney function.

- 23 people were treated once monthly with Rivfloza®
- 12 people received placebo (a substance with no active ingredients)

Too few people with PH2 were enrolled in the study to evaluate the effectiveness of Rivfloza® in PH2. Therefore, Rivfloza® is only approved for use in people with PH1.

Important Safety Information


What are the possible side effects of Rivfloza®?

The most common side effects of Rivfloza® include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.

Please click [here](#) for Prescribing Information.

For people 9 years and older with PH1 and relatively preserved kidney function

Rivfloza[®] reduces oxalate levels in the urine and keeps them under control




People with PH1 treated with Rivfloza[®] achieved an **average difference of 56% in 24-hour urinary oxalate** compared to placebo, measured monthly from 3 months to 6 months.

What was studied: The study evaluated the percent change in urinary oxalate from the start of the study. The amount of urinary oxalate was measured every 30 days.



All people who received Rivfloza[®] for an additional 6 months **maintained the reduction in urinary oxalate.**

What was studied: 13 people with PH1 continued to receive treatment with Rivfloza[®] in a long-term extension study.



3 out of 4 people with PH1 treated with Rivfloza[®] had reduced levels of oxalate in their urine, down to **normal or almost normal levels** after 6 months of study.

What was studied: 24-hour urine samples were collected and tested to determine whether patients' levels of urinary oxalate were normal or almost normal (elevated slightly above the normal range).

People who received placebo in the study had higher initial urinary oxalate levels.

Talk to your healthcare provider about what to expect from treatment.

Important Safety Information

What are the possible side effects of Rivfloza[®]?

The most common side effects of Rivfloza[®] include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.

Please click [here](#) for Prescribing Information.

 rivfloza[®]
(nedosiran) injection
80mg, 128mg, 160mg

For people 9 years and older with PH1 and relatively preserved kidney function

The only self- or caregiver-administered treatment for patients with PH1




At-home administration



- For people 12 years and older, Rivfloza® may be **self-administered**
- For children 9 to 11 years of age, Rivfloza® may be **administered by a caregiver** (after training and guidance from a healthcare provider for the single-dose vial)
- A healthcare provider will show you how to prepare and inject Rivfloza® subcutaneously (which means just under the skin)
- With the Rivfloza® prefilled syringe, the dose is premeasured



Once-a-month dosing

- Rivfloza® is administered once monthly at the recommended age- and weight-based dose as prescribed by your healthcare provider

Age 12+	Body weight	Dose per month	Administration
 Prefilled syringe	110 lbs or more (50 kg or more)	160 mg	The patient, a caregiver, or a healthcare provider may inject Rivfloza®.
	Less than 110 lbs (Less than 50 kg)	128 mg	

Ages 9-11	Body weight	Dose per month	Administration
 Prefilled syringe	110 lbs or more (50 kg or more)	160 mg	A caregiver or healthcare provider may inject Rivfloza®.
 Single-dose vial	Less than 110 lbs (Less than 50 kg)	3.3 mg/kg, not to exceed 128 mg	A healthcare provider, or a caregiver under the guidance of a healthcare provider, may inject Rivfloza®.

If you have any questions about taking Rivfloza®, please contact your healthcare provider.

Please click [here](#) for Prescribing Information.

Rivfloza[®] is safe and well-tolerated

No serious treatment-related side effects
in people with PH1
who received Rivfloza[®]
in the clinical study



- The most common side effects (occurring in 39% of people in the clinical study) were injection site reactions, such as reddening, pain, bruising, rash, or dimple at site of injection
- Injection site reactions were generally mild and did not lead to stopping treatment

Questions during treatment? Reach out to your healthcare provider.

LEARN MORE AT [Rivfloza.com](https://rivfloza.com)

Please click [here](#) for Prescribing Information.

 **rivfloza[®]**
(nedosiran) injection
80mg, 128mg, 160mg



NovoCare[®] provides support every step of the way

Once a NovoCare[®] Patient Enrollment Form (PEF) is submitted by your healthcare provider's office, a Case Manager will assist with insurance access and coverage. Case Managers help to ensure proper paperwork and documentation are submitted and provide expert guidance on the range of services available, including:



Benefit verification

Allows a healthcare provider's representative to request benefit verification by completing the PEF.



Appeals assistance

Offers support and information about the appeals process if insurance coverage is denied.



Live support for patients

Ensures every patient is assigned a dedicated Patient Liaison for treatment support.



JumpStart[™]

Provides limited free product to eligible patients experiencing a gap or delay in getting insurance coverage.



Prior authorization (PA) assistance

Helps navigate and streamline the insurance process.



Co-pay assistance

Provides financial assistance to eligible patients.



Injection training

Gives professional live, in-person, or virtual injection training for Rivfloza[®].



Patient Assistance Program (PAP)

Supports eligible patients prescribed Novo Nordisk medications free of charge.

Eligibility requirements may vary.

NovoCare[®] can be reached at (844) 906-5099, Monday-Friday (8 AM-8 PM ET) or through [NovoCare.com](https://www.novocare.com).

What is Rivfloza[®]?

Rivfloza[®] is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.

It is not known if Rivfloza[®] is safe and effective in children younger than 9 years of age.

Important Safety Information

What are the possible side effects of Rivfloza[®]?

The most common side effects of Rivfloza[®] include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.

Please click [here](#) for Prescribing Information.